Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
87725257 |
LAW OFFICE ASSIGNED |
LAW OFFICE 115 |
MARK SECTION |
MARK |
OSPREY THERAPEUTICS (see, http://uspto.report/TM/87725257/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
OSPREY THERAPEUTICS |
OWNER SECTION (current) |
NAME |
Ionis Pharmaceuticals, Inc. |
MAILING ADDRESS |
2855 Gazelle Court |
CITY |
Carlsbad |
STATE |
California |
ZIP/POSTAL CODE |
92010 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
OWNER SECTION (proposed) |
NAME |
Ionis Pharmaceuticals, Inc. |
MAILING ADDRESS |
2855 Gazelle Court |
CITY |
Carlsbad |
STATE |
California |
ZIP/POSTAL CODE |
92010 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Anne H. Peck |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@cooley.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
apeck@cooley.com; dkoons@cooley.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Anne H. Peck |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@cooley.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
apeck@cooley.com; dkoons@cooley.com; bfocarino@cooley.com |
DOCKET/REFERENCE NUMBER |
097721-20084 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations and human therapeutic preparations for treating and preventing amyloidosis, genetic diseases, disorders and
conditions, and protein diseases, disorders and conditions; pharmaceutical preparations and human therapeutic preparations for treating neuropathy, neurological dysfunction, and damage to nerves,
tissue, organs, intestinal tract, or bone marrow; injectable drugs for reducing production of transthyretin; antisense drugs |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
4 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
07/10/2018 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/Clifford E Ford/ |
SIGNATORY'S NAME |
Ford, Clifford E. |
SIGNATORY'S POSITION |
Vice President, Patents and Senior Patent Counsel |
DATE SIGNED |
06/30/2020 |
SIGNATORY'S PHONE NUMBER |
650-843-5000 |
FILING INFORMATION |
SUBMIT DATE |
Tue Jun 30 19:17:47 ET 2020 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XXX.XXX-
20200630191747155940-8772
5257-7104de7a3521dfb5ab87
74ef9dc7cc2d07065cb75edd3
4c4c23c04c9d5940-DA-17467
314-20200630161650502458 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: OSPREY THERAPEUTICS (see, http://uspto.report/TM/87725257/mark.png)
SERIAL NUMBER: 87725257
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Ionis Pharmaceuticals, Inc., having an address of
2855 Gazelle Court
Carlsbad, California 92010
United States
Proposed: Ionis Pharmaceuticals, Inc., having an address of
2855 Gazelle Court
Carlsbad, California 92010
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 07/10/2018.
For International Class 005:
Current identification: Pharmaceutical preparations and human therapeutic preparations for treating and preventing amyloidosis, genetic diseases, disorders and conditions, and protein diseases,
disorders and conditions; pharmaceutical preparations and human therapeutic preparations for treating neuropathy, neurological dysfunction, and damage to nerves, tissue, organs, intestinal tract, or
bone marrow; injectable drugs for reducing production of transthyretin; antisense drugs
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
Anne H. Peck
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): apeck@cooley.com; dkoons@cooley.com
Correspondence Information (proposed):
Anne H. Peck
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): apeck@cooley.com; dkoons@cooley.com; bfocarino@cooley.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Clifford E Ford/ Date Signed: 06/30/2020
Signatory's Name: Ford, Clifford E.
Signatory's Position: Vice President, Patents and Senior Patent Counsel
Signatory's Phone: 650-843-5000
RAM Sale Number: 87725257
RAM Accounting Date: 06/30/2020
Serial Number: 87725257
Internet Transmission Date: Tue Jun 30 19:17:47 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-202006301917471
55940-87725257-7104de7a3521dfb5ab8774ef9
dc7cc2d07065cb75edd34c4c23c04c9d5940-DA-
17467314-20200630161650502458